Quantitative measurements of HER2 expression and HER2: HER2 dimerization identify subgroups of HER2 positive metastatic breast cancer patients with different probabilities of response to trastuzumab treatment

被引：0
|
作者：
Huang, W.
Lipton, A.
Leitzel, K.
Ali, S. M.
Fuchs, E. M.
Weidler, J.
Chappey, C.
Sperinde, J.
Tan, Y.
Jin, X.
Paquet, A.
Winston, J.
Petropoulos, C.
Kostler, W. J.
Bates, M.
机构：
[1] Monogram Biosci Inc, San Francisco, CA USA
[2] Milton S Hershey Med Ctr, Hershey, PA USA
[3] Med Univ Vienna, Vienna, Austria
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S86 / S86
页数：1
相关论文
共 50 条
  • [1] Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2: HER2 dimerization in a clinic-based cohort of patients with metastatic breast cancer
    Toi, M.
    Sperinde, J.
    Huang, W.
    Saji, S.
    Ohno, S.
    Nakamura, S.
    Iwata, H.
    Masuda, N.
    Aogi, K.
    Bates, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer.
    Bachmeier, Beatrice
    Sperinde, Jeff
    Weidler, Jodi Marie
    Lie, Yolanda
    Chenna, Ahmed
    Winslow, John
    Engel, Jutta
    Schubert-Fritschle, Gabriele
    Sommerhoff, Christian
    Petropoulos, Christos J.
    Bates, Michael Patrick
    Huang, Weidong
    Nerlich, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] HER2 expression and HER2:HER2 dimerization identifies subpopulations of metastatic breast cancer patients with different probabilities of long-term survival following trastuzumab treatment and with different requirements for concomitant chemotherapy
    Bates, M. P.
    Desmedt, C.
    Sperinde, J.
    Huang, W.
    Larsimont, D.
    Durbecq, V.
    Winslow, J.
    Chappey, C.
    Piccart, M.
    Sotiriou, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH
    Desmedt, Christine
    Sperinde, Jeff
    Piette, Fanny
    Huang, Weidong
    Jin, Xueguang
    Tan, Yuping
    Durbecq, Virginie
    Larsimont, Denis
    Giuliani, Rosa
    Chappey, Colombe
    Buyse, Marc
    Winslow, John
    Piccart, Martine
    Sotiriou, Christos
    Petropoulos, Christos
    Bates, Michael
    DIAGNOSTIC MOLECULAR PATHOLOGY, 2009, 18 (01) : 22 - 29
  • [5] HER2 status in breast cancer patients: A comparison between borderline positive HER2 and strongly positive HER2 tumors
    Huszno, J.
    Nowara, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S137 - S137
  • [6] Evaluation of analytical accuracy of HER2 status in patients with breast cancer Comparison of HER2 GPA with HER2 IHC and HER2 FISH
    Jensen, Steffen Grann
    Thomas, Peter Engel
    Christensen, Ib Jarle
    Balslev, Eva
    Hansen, Alastair
    Hogdall, Estrid
    APMIS, 2020, 128 (11) : 573 - 582
  • [7] Reassessment of HER2 status in HER2 negative or HER2 unknown breast cancer patients with recurrent metastatic disease by analyzing serum HER2 and HER2 status of circulating tumor cells.
    Fehm, T.
    Lane, N.
    Solomayer, E.
    Wallwiener, D.
    Uhr, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S40 - S40
  • [8] Differential response of HER2 positive breast cancer based on HER2 protein expression level
    Atallah, N. M.
    Toss, M. S.
    Al Saleem, M.
    Green, A. R.
    Mongan, N. P.
    Rakha, E. A.
    JOURNAL OF PATHOLOGY, 2023, 261 : S9 - S9
  • [9] HER2 or not HER2: That is the question
    Burstein, HJ
    Winer, EP
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 3656 - 3659
  • [10] Prognostic significance and evolution of HER2 zero, HER2 low and HER2 positive in breast cancer after neoadjuvant treatment
    Wei, T.
    Wang, D.
    Peng, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S301 - S302
12345